Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1957 1
1961 1
1962 3
1963 6
1964 8
1965 8
1966 5
1967 8
1968 12
1969 20
1970 7
1971 18
1972 6
1973 10
1974 10
1975 15
1976 22
1977 14
1978 10
1979 10
1980 22
1981 25
1982 27
1983 25
1984 14
1985 38
1986 23
1987 32
1988 35
1989 48
1990 36
1991 60
1992 56
1993 68
1994 64
1995 59
1996 76
1997 65
1998 80
1999 89
2000 92
2001 76
2002 93
2003 97
2004 84
2005 101
2006 117
2007 110
2008 129
2009 138
2010 163
2011 165
2012 162
2013 171
2014 148
2015 124
2016 146
2017 143
2018 146
2019 158
2020 160
2021 155
2022 129
2023 120
2024 63

Text availability

Article attribute

Article type

Publication date

Search Results

3,963 results

Results by year

Filters applied: . Clear all
Page 1
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Subbiah V, et al. Among authors: takeda m. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12. Lancet Oncol. 2022. PMID: 36108661 Clinical Trial.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M. Paz-Ares LG, et al. Among authors: takeda m. J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12. J Thorac Oncol. 2022. PMID: 34648948 Free article. Clinical Trial.
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Hata A, et al. Among authors: takeda m. J Clin Oncol. 2022 Jan 10;40(2):180-188. doi: 10.1200/JCO.21.01315. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793245 Free PMC article. Clinical Trial.
Radical electron-induced cellulose-semiconductors.
Fukuhara M, Yokotsuka T, Samoto T, Kumadaki M, Takeda M, Hashida T. Fukuhara M, et al. Among authors: takeda m. Sci Rep. 2024 Apr 15;14(1):8692. doi: 10.1038/s41598-024-59499-1. Sci Rep. 2024. PMID: 38622278 Free PMC article.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S. John T, et al. Among authors: takeda m. Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19. Int J Clin Oncol. 2022. PMID: 35182247 Free PMC article. Clinical Trial.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Hayashi H, et al. Among authors: takeda m. J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318. J Clin Invest. 2024. PMID: 38557498 Free PMC article.
Lactate Metabolism and Satellite Cell Fate.
Nalbandian M, Radak Z, Takeda M. Nalbandian M, et al. Among authors: takeda m. Front Physiol. 2020 Dec 11;11:610983. doi: 10.3389/fphys.2020.610983. eCollection 2020. Front Physiol. 2020. PMID: 33362583 Free PMC article. Review.
Proteolytic activation of SARS-CoV-2 spike protein.
Takeda M. Takeda M. Microbiol Immunol. 2022 Jan;66(1):15-23. doi: 10.1111/1348-0421.12945. Epub 2021 Oct 12. Microbiol Immunol. 2022. PMID: 34561887 Free PMC article. Review.
3,963 results